TEM•Bristol Myers Squibb entered multi-year collaborations with Pathos AI and Tempus AI to advance AI-driven drug development for neurological diseases. Pathos will license a de-identified dataset from Tempus under a five-year, $55 million agreement.
Bristol Myers Squibb will lead Pathos AI's Series E financing and gain access to its Pathos Foundry AI platform across its broader research and development portfolio. The companies also plan to use three-year exclusive neuroscience rights to improve clinical-trial design for Alzheimer's disease and other neurological conditions; Tempus will build a longitudinal dataset covering hundreds of thousands of patients, which Pathos will license for disease research and more targeted trials.
